{"id":2918,"date":"2026-03-19T13:13:47","date_gmt":"2026-03-19T13:13:47","guid":{"rendered":"https:\/\/economicowl.com\/?p=2918"},"modified":"2026-03-20T13:22:12","modified_gmt":"2026-03-20T13:22:12","slug":"this-2-biotech-stock-could-be-the-next-1000-winner","status":"publish","type":"post","link":"https:\/\/economicowl.com\/?p=2918","title":{"rendered":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner"},"content":{"rendered":"\n<p>Every once in a while, a stock comes along that has the potential to completely change your financial future.<\/p>\n\n\n\n<p>Not 10%.<\/p>\n\n\n\n<p>Not 50%.<\/p>\n\n\n\n<p>We\u2019re talking about <strong>500%, 1,000%\u2026 or more.<\/strong><\/p>\n\n\n\n<p>And almost every time, those opportunities show up in one place:<\/p>\n\n\n\n<p>\ud83d\udc49 <strong>Biotech.<\/strong><\/p>\n\n\n\n<p>Because in biotech, everything can change overnight.<\/p>\n\n\n\n<p>A single breakthrough.<\/p>\n\n\n\n<p>A single announcement.<\/p>\n\n\n\n<p>A single FDA milestone.<\/p>\n\n\n\n<p>And suddenly, a tiny unknown company becomes the <strong>hottest stock on the market.<\/strong><\/p>\n\n\n\n<p><strong>We\u2019ve Already Seen This Play Out<\/strong><\/p>\n\n\n\n<p>Not long ago, we identified <strong>Celcuity (CELC)<\/strong> at just <strong>$8 per share<\/strong>.<\/p>\n\n\n\n<p>At the time, almost nobody was paying attention.<\/p>\n\n\n\n<p>Then the market woke up.<\/p>\n\n\n\n<p>CELC exploded past <strong>$105 per share<\/strong>\u2026<\/p>\n\n\n\n<p>\ud83d\udc49 A gain of over <strong>1,000% in just months.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" width=\"968\" height=\"564\" src=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\" alt=\"\" class=\"wp-image-2924\" style=\"aspect-ratio:1.7163654939020496;width:376px;height:auto\" srcset=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png 968w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc-300x175.png 300w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc-768x447.png 768w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc-860x501.png 860w\" sizes=\"auto, (max-width: 968px) 100vw, 968px\" \/><\/figure>\n\n\n\n<p>By the time it was trending?<\/p>\n\n\n\n<p>It was already too late.<\/p>\n\n\n\n<p><strong>Now It\u2019s Happening Again\u2026<\/strong><\/p>\n\n\n\n<p>Right now, a powerful shift is taking place in medicine\u2014one that could create the <strong>next wave of explosive biotech winners.<\/strong><\/p>\n\n\n\n<p><strong>Stem Cells Are No Longer \u201cExperimental\u201d<\/strong><\/p>\n\n\n\n<p>This isn\u2019t hype anymore.<\/p>\n\n\n\n<p>Stem cells are already being used to treat some of the most serious diseases on the planet, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Leukemia<\/li>\n\n\n\n<li>Lymphoma<\/li>\n\n\n\n<li>Multiple myeloma<\/li>\n<\/ul>\n\n\n\n<p>Even more shocking?<\/p>\n\n\n\n<p>In 2024, the World Health Organization confirmed another case of <strong>HIV remission<\/strong> tied to a stem cell transplant.<\/p>\n\n\n\n<p>\ud83d\udc49 That\u2019s not theory. That\u2019s real-world impact.<\/p>\n\n\n\n<p><strong>And Now AI Is Pouring Fuel on the Fire<\/strong><\/p>\n\n\n\n<p>If stem cells are revolutionizing treatment\u2026<\/p>\n\n\n\n<p><strong>Artificial Intelligence is accelerating it at an unprecedented pace.<\/strong><\/p>\n\n\n\n<p>AI is helping researchers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Discover treatments faster<\/li>\n\n\n\n<li>Predict patient outcomes<\/li>\n\n\n\n<li>Optimize therapies in real time<\/li>\n<\/ul>\n\n\n\n<p>This combination is creating a <strong>perfect storm for massive breakthroughs\u2014and massive stock moves.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized is-style-rounded\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" width=\"626\" height=\"417\" src=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull.avif\" alt=\"\" class=\"wp-image-2927\" style=\"width:260px;height:auto\" srcset=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull.avif 626w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull-300x200.avif 300w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull-330x220.avif 330w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull-420x280.avif 420w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/bull-615x410.avif 615w\" sizes=\"auto, (max-width: 626px) 100vw, 626px\" \/><\/figure>\n\n\n\n<p data-wp-context---core-fit-text=\"core\/fit-text::{&quot;fontSize&quot;:&quot;&quot;}\" data-wp-init---core-fit-text=\"core\/fit-text::callbacks.init\" data-wp-interactive data-wp-style--font-size=\"core\/fit-text::context.fontSize\" class=\"has-fit-text\"><strong>Enter: Noveris Health Sciences (Symbol: NVRS)<\/strong><\/p>\n\n\n\n<p>Trading at around <strong>$2 per share<\/strong>, this under-the-radar company is quietly positioning itself at the intersection of:<\/p>\n\n\n\n<p>\ud83d\udc49 Stem Cells<\/p>\n\n\n\n<p>\ud83d\udc49 Artificial Intelligence<\/p>\n\n\n\n<p>\ud83d\udc49 Regenerative Medicine<\/p>\n\n\n\n<p>And almost nobody is paying attention\u2026 yet.<\/p>\n\n\n\n<p><strong><span style=\"text-decoration: underline;\">Why NVRS Could Explode<\/span><\/strong><\/p>\n\n\n\n<p><strong>1. AI-Driven Biotech Platform<\/strong><\/p>\n\n\n\n<p>Noveris isn\u2019t just developing treatments\u2014it\u2019s building a <strong>smart system<\/strong> that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Personalizes therapies<\/li>\n\n\n\n<li>Predicts outcomes<\/li>\n\n\n\n<li>Tracks results in real time<\/li>\n<\/ul>\n\n\n\n<p>That\u2019s a <em>huge<\/em> competitive edge.<\/p>\n\n\n\n<p><strong>2. Multiple Breakthrough Opportunities<\/strong><\/p>\n\n\n\n<p>Most biotech companies rely on one big gamble.<\/p>\n\n\n\n<p>NVRS doesn\u2019t.<\/p>\n\n\n\n<p>It\u2019s developing <strong>adipose-derived stem cell therapies<\/strong> using:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patient-specific treatments<\/li>\n\n\n\n<li>Off-the-shelf solutions<\/li>\n<\/ul>\n\n\n\n<p>\ud83d\udc49 Multiple paths = multiple chances for a breakout.<\/p>\n\n\n\n<p><strong>3. A Hidden Asset That Could Be Game-Changin<\/strong>g<\/p>\n\n\n\n<p>The company controls a <strong>proprietary stem cell library<\/strong>\u2014a potential goldmine as demand for regenerative medicine explodes.<\/p>\n\n\n\n<p><strong>4. Positioned for a Major Catalyst<\/strong><\/p>\n\n\n\n<p>And in biotech, one major regulatory milestone can send a stock into the stratosphere overnight.<\/p>\n\n\n\n<p><strong>Don\u2019t Miss This Moment<\/strong><\/p>\n\n\n\n<p>Think about it:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Early investors in <a href=\"chatgpt:\/\/generic-entity?number=0\">Eli Lilly<\/a> saw massive gains as its treatments took off<\/li>\n\n\n\n<li><a href=\"chatgpt:\/\/generic-entity?number=1\">Novo Nordisk<\/a> turned into a global powerhouse<\/li>\n\n\n\n<li>CELC delivered <strong>1,000%+ returns<\/strong><\/li>\n<\/ul>\n\n\n\n<p>All of them had one thing in common:<\/p>\n\n\n\n<p>They were overlooked\u2026 until they weren\u2019t.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"800\" src=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/stocksoar.webp\" alt=\"\" class=\"wp-image-2931\" style=\"width:206px;height:auto\" srcset=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/stocksoar.webp 800w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/stocksoar-300x300.webp 300w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/stocksoar-150x150.webp 150w, https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/stocksoar-768x768.webp 768w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/figure>\n\n\n\n<p><strong>NVRS<\/strong> is still early. Still cheap. Still under the radar, and there is still time to buy it today. Will <strong>NVRS<\/strong> be the next 10x stock? The upside could be life-changing.<\/p>\n\n\n\n<p><strong><span style=\"text-decoration: underline;\">At around $2 per share, it\u2019s the kind of opportunity that one must quickly seize.<\/span><\/strong><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p style=\"font-size:8px\">This communication is provided for informational and marketing purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction. The author is not registered as an investment advisor, portfolio manager, or dealer under applicable securities legislation in Canada or any other jurisdiction. The information contained herein does not constitute investment advice, financial advice, or a recommendation to buy or sell any securities. This communication is not tailored to the investment objectives, financial situation, or needs of any specific individual. High-Risk Warning: Investing in publicly traded securities\u2014particularly micro-cap, small-cap, or early-stage companies\u2014involves a high degree of risk, including the potential loss of your entire investment. Such securities may be highly volatile, illiquid, and subject to significant price fluctuations. Conflict of Interest Disclosure: The author currently holds a long position in the securities of the company discussed in this communication, including approximately 50,000 shares, which were acquired in the open market prior to initiating coverage. Accordingly, the author has a direct financial interest in the performance of the company\u2019s stock and this constitutes a material conflict of interest. The author intends to sell shares of the company and may do so at any time, including during or shortly after the publication of this communication, without notice to readers. As a result, the author may benefit from any increase in the market price or trading volume of the securities discussed. No Independent Verification: The information contained herein has been obtained from sources believed to be reliable; however, it has not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. Any reliance placed on such information is strictly at the reader\u2019s own risk. Forward-Looking Statements: This communication may contain forward-looking statements, including but not limited to statements regarding future performance, potential returns, regulatory developments, and market opportunities. These statements are based on current expectations, estimates, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. No Liability: To the fullest extent permitted by law, the author and any affiliated parties disclaim any liability whatsoever for any direct, indirect, or consequential loss arising from the use of, or reliance on, this communication. Independent Advice Recommended: Readers are strongly encouraged to conduct their own due diligence and consult with a licensed investment professional before making any investment decisions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Every once in a while, a stock comes along that has the potential to completely change your financial future. Not 10%. Not 50%. We\u2019re talking about 500%, 1,000%\u2026 or more. And almost every time, those opportunities show up in one place: \ud83d\udc49 Biotech. Because in biotech, everything can change overnight. A single breakthrough. A single [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106],"tags":[],"tmauthors":[1056],"ppma_author":[344],"class_list":{"0":"post-2918","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicowl.com\/?p=2918\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl\" \/>\n<meta property=\"og:description\" content=\"Every once in a while, a stock comes along that has the potential to completely change your financial future. Not 10%. Not 50%. We\u2019re talking about 500%, 1,000%\u2026 or more. And almost every time, those opportunities show up in one place: \ud83d\udc49 Biotech. Because in biotech, everything can change overnight. A single breakthrough. A single [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicowl.com\/?p=2918\" \/>\n<meta property=\"og:site_name\" content=\"Economic Owl\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-19T13:13:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T13:22:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"968\" \/>\n\t<meta property=\"og:image:height\" content=\"564\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Andrew Collins\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrew Collins\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/economicowl.com\/?p=2918#article\",\"isPartOf\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918\"},\"author\":{\"name\":\"Andrew Collins\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/3aaa12b1101d91e41ffd7b246e2542b3\"},\"headline\":\"This Undervalued Biotech Stock Could Be the Next 1,000% Winner\",\"datePublished\":\"2026-03-19T13:13:47+00:00\",\"dateModified\":\"2026-03-20T13:22:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918\"},\"wordCount\":921,\"publisher\":{\"@id\":\"https:\/\/economicowl.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918#primaryimage\"},\"thumbnailUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/economicowl.com\/?p=2918\",\"url\":\"https:\/\/economicowl.com\/?p=2918\",\"name\":\"This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl\",\"isPartOf\":{\"@id\":\"https:\/\/economicowl.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918#primaryimage\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918#primaryimage\"},\"thumbnailUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\",\"datePublished\":\"2026-03-19T13:13:47+00:00\",\"dateModified\":\"2026-03-20T13:22:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/economicowl.com\/?p=2918#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/economicowl.com\/?p=2918\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/?p=2918#primaryimage\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png\",\"width\":968,\"height\":564},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/economicowl.com\/?p=2918#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/economicowl.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"This Undervalued Biotech Stock Could Be the Next 1,000% Winner\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/economicowl.com\/#website\",\"url\":\"https:\/\/economicowl.com\/\",\"name\":\"Economic Owl\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/economicowl.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/economicowl.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/economicowl.com\/#organization\",\"name\":\"Economic Owl\",\"url\":\"https:\/\/economicowl.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png\",\"width\":800,\"height\":150,\"caption\":\"Economic Owl\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/3aaa12b1101d91e41ffd7b246e2542b3\",\"name\":\"Andrew Collins\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/image\/41cc9927a33bb4c1373c6b1a9f96b1a1\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png\",\"caption\":\"Andrew Collins\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicowl.com\/?p=2918","og_locale":"en_US","og_type":"article","og_title":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl","og_description":"Every once in a while, a stock comes along that has the potential to completely change your financial future. Not 10%. Not 50%. We\u2019re talking about 500%, 1,000%\u2026 or more. And almost every time, those opportunities show up in one place: \ud83d\udc49 Biotech. Because in biotech, everything can change overnight. A single breakthrough. A single [&hellip;]","og_url":"https:\/\/economicowl.com\/?p=2918","og_site_name":"Economic Owl","article_published_time":"2026-03-19T13:13:47+00:00","article_modified_time":"2026-03-20T13:22:12+00:00","og_image":[{"width":968,"height":564,"url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png","type":"image\/png"}],"author":"Andrew Collins","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Andrew Collins","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicowl.com\/?p=2918#article","isPartOf":{"@id":"https:\/\/economicowl.com\/?p=2918"},"author":{"name":"Andrew Collins","@id":"https:\/\/economicowl.com\/#\/schema\/person\/3aaa12b1101d91e41ffd7b246e2542b3"},"headline":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner","datePublished":"2026-03-19T13:13:47+00:00","dateModified":"2026-03-20T13:22:12+00:00","mainEntityOfPage":{"@id":"https:\/\/economicowl.com\/?p=2918"},"wordCount":921,"publisher":{"@id":"https:\/\/economicowl.com\/#organization"},"image":{"@id":"https:\/\/economicowl.com\/?p=2918#primaryimage"},"thumbnailUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png","articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicowl.com\/?p=2918","url":"https:\/\/economicowl.com\/?p=2918","name":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner - Economic Owl","isPartOf":{"@id":"https:\/\/economicowl.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicowl.com\/?p=2918#primaryimage"},"image":{"@id":"https:\/\/economicowl.com\/?p=2918#primaryimage"},"thumbnailUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png","datePublished":"2026-03-19T13:13:47+00:00","dateModified":"2026-03-20T13:22:12+00:00","breadcrumb":{"@id":"https:\/\/economicowl.com\/?p=2918#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicowl.com\/?p=2918"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/?p=2918#primaryimage","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/03\/celc.png","width":968,"height":564},{"@type":"BreadcrumbList","@id":"https:\/\/economicowl.com\/?p=2918#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicowl.com\/"},{"@type":"ListItem","position":2,"name":"This Undervalued Biotech Stock Could Be the Next 1,000% Winner"}]},{"@type":"WebSite","@id":"https:\/\/economicowl.com\/#website","url":"https:\/\/economicowl.com\/","name":"Economic Owl","description":"","publisher":{"@id":"https:\/\/economicowl.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicowl.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicowl.com\/#organization","name":"Economic Owl","url":"https:\/\/economicowl.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/#\/schema\/logo\/image\/","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png","width":800,"height":150,"caption":"Economic Owl"},"image":{"@id":"https:\/\/economicowl.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/economicowl.com\/#\/schema\/person\/3aaa12b1101d91e41ffd7b246e2542b3","name":"Andrew Collins","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/#\/schema\/person\/image\/41cc9927a33bb4c1373c6b1a9f96b1a1","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png","caption":"Andrew Collins"}}]}},"authors":[{"term_id":344,"user_id":7,"is_guest":0,"slug":"nf084wh80wtg8","display_name":"Andrew Collins","avatar_url":{"url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png","url2x":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Author-Economic-Owl.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2918"}],"version-history":[{"count":12,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2918\/revisions"}],"predecessor-version":[{"id":2952,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2918\/revisions\/2952"}],"wp:attachment":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2918"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftmauthors&post=2918"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=2918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}